Ruby on Rails Development Companies in India.... Contd.
Ruby on Rails provides a framework enables applications to be developed in a faster and simpler ...
Reliance, India's most admired Business House
The Reliance Group has emerged as the 'most admired business house' for the third consecutive yea...
Ranbaxy Sellout - The Daiichi Acquisition
Category: Events, Business & Finance, News | Tags: Ranbaxy, Daiishi, Malvinder Singh, Singh, pharma companies, pharmaceutical industry, drug, majority stake sell out, stakes, stakes sell out , Ranbaxy stake sale, Ranbaxy Sell out

Related Guides
General Elections 2009
It takes a month to elect a new leader in the world?s largest democracy. India is currently holding general elections?the largest democratic election in the ...
Mumbai Airport -The best airport in India
Mumbai airport has been voted the best airport in India in a survey conducted by the Airport International Council, a body of operators who collectively mana...
The Mumbai Blues - Monsoons
In recent years, Mumbai has been facing the most brunts of heavy monsoons in India. Right from the dark days of June 2005, the monsoons in Mumbai have been s...
iPhone 2.0 unveiled
There has been speculations about the availability of Apple approved 'unlocked' iPhones in Asian markets. Markets are awaiting for the latest iPhone release...
Rangoli - Colors of India
Rangoli is basically floor painting using colored sand, flowers, clay lamps or rice. It is one such creative expression which is found in all parts of the co...
Guide Comments
Asrar said about 1 year ago:
From strictly business point of view, it is a great deal. The shareholders make huge money and live happily ever after. However, it is a dangerous trend for the following reasons: 1. Generic industry is based on low prices. Such acquisitions will lead to prices increases and thus the loss of primary advantage. 2. Indigenous companies do care about their own countries/people in some way. They also take pride in achievements as it highlights their origin. After such acquisitions, that spirit is lost. 3. Every time Ranbaxy achieved a new landmark abroad, their local consumer base automatically increased due to increased confidence and pride. This advantage will be lost. 4. All great businesses have an emotional component (Walmart, GE, GM, Welgreen, Siemens, Daimler Benz, Ferrari etc). It a driving force and a source of sustained invisible support. Acquisitions like this one lose that and will face very serious challenge in the long term. In the short term they make money quickly but not for long. We have seen that a big name built over years goes into oblivion forever. I hope it does not happen to Ranbaxy.
Guide Discussion & Comments
blog comments powered by DisqusMOST POPULAR - GUIDES
- Jog Waterfalls -The Tallest in India
- Queen of the Hills: Shimla
- India Travel Guide101: Obtaining a Visa fo...
- Monsoons : The Best Time to Getaway
- The Scintillating Beaches of Goa
- You know you're on an Indian Road when...
- Hindu Deities- All about the Gods
- 10 Reasons Why India MUST be on your List ...
- What attracts tourists to Goa?
- Goa Churches & Religious Places In Goa, India
Hi there,I am Avocados






In an unexpected and stunning move, one of the country's largest and fast growing pharmaceutical Company, Ranbaxy has sold its majority stake of more than 50 percent to Japanese drug firm Daiichi Sankyo. On Tuesday June 11, Daiichi Sankyo announced the acquisition of the stake for over Rs.15000 crores.


There has been speculations that after the acquisition of Ranbaxy, many other companies may follow suit. This deal makes Japanese firm Daiichi the 15th biggest drugmaker in the world. Malvinder Singh will continue as CEO and MD and the company will retain its name. The Singh family would net in about Rs 10,000 crore by selling their stake. Malvinder Singh would also assume the position of chairman of the board upon the deal's closure that is expected by March 2009. The Japanese firm would acquire the entire 34.82 per cent stake from its current promoters Malvinder Singh and family. Also Daiichi would make an open offer for an additional 20 per cent stake in Ranbaxy at a price of Rs 737 per share which represents a premium of over 50 per cent on the average price over the last three months.








5.0 star rating
1 












